安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Proteinase-activated receptor 1 - Wikipedia
Proteinase-activated receptor 1 (PAR1) also known as protease-activated receptor 1, coagulation factor II receptor and thrombin receptor is a protein that in humans is encoded by the F2R gene [5] PAR1 is a G protein-coupled receptor and one of four protease-activated receptors involved in the regulation of thrombotic response
- Protease-activated receptor-1 (PAR-1): a promising molecular target for . . .
PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo Oncogene 2016;35:3817–28 doi: 10 1038 onc 2015 452 https: doi org 10 1038 onc 2015 452
- Protease-aktivierte Rezeptoren – Wikipedia
Es werden vier PAR-Isoformen unterschieden (PAR1–4), von denen PAR1, PAR3 und PAR4 unter physiologischen Bedingungen durch Thrombin aktiviert werden können
- Protease-aktivierter Rezeptor - DocCheck Flexikon
Die Protease-aktivierten Rezeptoren, kurz PARs, sind eine Familie von G-Protein-gekoppelten Rezeptoren, die sich dadurch auszeichnen, dass sie durch Serinproteasen (v a Thrombin) aktiviert werden Neben ihrer Rolle bei der Blutgerinnung sind Protease-aktivierte Rezeptoren auch an Entzündungs- und Verdauungsprozessen beteiligt
- F2R Gene - GeneCards | PAR1 Protein | PAR1 Antibody
( par1_human,p25116) Tocris Summary for F2R Gene Protease-activated receptors (PARs, also known as thrombin receptors) are G-protein-coupled receptors, activated by cleavage of their N-terminal domains by serine proteases
- Structural basis of tethered agonism and G protein coupling of protease . . .
Protease-activated receptor 1 (PAR1) is a key member of this family and is recognized as a critical pharmacological target for managing thrombotic disorders
- Protease-activated receptor - Wikipedia
This protein, which was eventually given the designation protease-activated receptor 1 (PAR1), was the first to be recognized as a member of the PAR family A second thrombin-activated protein, later known as PAR3, was identified in 1994
- Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung . . .
PAR1 inhibitor PZ-128 is in a Phase II clinical trial and is being developed to prevent ischemic and thrombotic complication of patients undergoing cardiac catheterization
|
|
|